HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ann-Lii Cheng Selected Research

Adenocarcinoma

1/2021Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
1/2020Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
8/2018A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma.
1/2017Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.
1/2016Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice.
7/2014Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
1/2011Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
6/2008Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
8/2005Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ann-Lii Cheng Research Topics

Disease

175Neoplasms (Cancer)
12/2023 - 01/2002
173Hepatocellular Carcinoma (Hepatoma)
02/2024 - 01/2003
38Breast Neoplasms (Breast Cancer)
12/2023 - 11/2002
23Lymphoma (Lymphomas)
01/2020 - 06/2003
19Neoplasm Metastasis (Metastasis)
01/2023 - 11/2002
18Liver Neoplasms (Liver Cancer)
12/2023 - 01/2011
18Colorectal Neoplasms (Colorectal Cancer)
01/2023 - 02/2002
17Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
02/2023 - 08/2005
14Infections
02/2023 - 11/2002
13Carcinoma (Carcinomatosis)
04/2013 - 04/2002
12Hypertension (High Blood Pressure)
02/2024 - 10/2013
12Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
12/2023 - 09/2005
12Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 03/2006
11Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2023 - 01/2005
10Disease Progression
01/2022 - 09/2005
9Adenocarcinoma
01/2021 - 08/2005
8Hepatitis
02/2023 - 06/2003
8Fatigue
01/2021 - 01/2009
7B-Cell Lymphoma (Lymphoma, B Cell)
04/2019 - 10/2007
7Hepatitis B
01/2018 - 03/2008
7Stomach Neoplasms (Stomach Cancer)
01/2014 - 03/2004
6Brain Neoplasms (Brain Tumor)
12/2023 - 06/2010
6Carcinogenesis
01/2023 - 05/2011
6Esophageal Squamous Cell Carcinoma
10/2022 - 07/2007
6Colonic Neoplasms (Colon Cancer)
12/2017 - 04/2004
5Urinary Bladder Neoplasms (Bladder Cancer)
01/2023 - 10/2009
5Lung Neoplasms (Lung Cancer)
05/2020 - 03/2010
5Diarrhea
01/2020 - 01/2007
5Nausea
05/2018 - 02/2006
5Adenocarcinoma of Lung
10/2013 - 08/2005
4Fibrosis (Cirrhosis)
04/2022 - 07/2004
4Vomiting
08/2018 - 02/2006
4Ascites
01/2018 - 09/2005
4Neutropenia
10/2017 - 03/2006
4Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2015 - 03/2008

Drug/Important Bio-Agent (IBA)

79Sorafenib (BAY 43-9006)FDA Link
02/2024 - 01/2009
27Biomarkers (Surrogate Marker)IBA
10/2022 - 10/2007
25Cisplatin (Platino)FDA LinkGeneric
12/2023 - 04/2002
25Fluorouracil (Carac)FDA LinkGeneric
06/2019 - 02/2002
20Leucovorin (Folinic Acid)FDA Link
06/2019 - 02/2002
19Bevacizumab (Avastin)FDA Link
12/2023 - 05/2009
17Proteins (Proteins, Gene)FDA Link
01/2021 - 08/2005
16GemcitabineFDA Link
01/2020 - 08/2005
16Phosphotransferases (Kinase)IBA
09/2019 - 09/2009
13atezolizumabIBA
02/2024 - 01/2020
13DNA (Deoxyribonucleic Acid)IBA
10/2023 - 01/2006
13Paclitaxel (Taxol)FDA LinkGeneric
07/2022 - 11/2002
12cabozantinibIBA
02/2024 - 07/2018
11Aspartate Aminotransferases (Aspartate Transaminase)IBA
02/2024 - 01/2012
11Immune Checkpoint InhibitorsIBA
09/2023 - 01/2018
11Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 07/2003
10Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2017 - 04/2004
9lenvatinibIBA
01/2024 - 01/2018
9pembrolizumabIBA
12/2023 - 01/2018
9ErbB Receptors (EGF Receptor)IBA
07/2021 - 08/2005
8Estrogen ReceptorsIBA
07/2021 - 01/2013
8NF-kappa B (NF-kB)IBA
07/2012 - 04/2002
7Alanine Transaminase (SGPT)IBA
02/2024 - 07/2012
7Rituximab (Mabthera)FDA Link
12/2023 - 02/2012
7Anti-Bacterial Agents (Antibiotics)IBA
02/2023 - 09/2005
7Cetuximab (Erbitux)FDA Link
01/2023 - 09/2014
7Bortezomib (Velcade)FDA Link
01/2013 - 08/2008
6Tyrosine Kinase InhibitorsIBA
01/2024 - 10/2013
6Estrogens (Estrogen)FDA Link
01/2023 - 12/2008
6Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2022 - 05/2012
6LigandsIBA
10/2021 - 04/2009
6Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
02/2015 - 04/2009
5Etoposide (VP 16)FDA LinkGeneric
12/2023 - 04/2015
5Antiviral Agents (Antivirals)IBA
01/2023 - 01/2012
5Histone Deacetylase InhibitorsIBA
01/2023 - 10/2007
5Thalidomide (Thalomid)FDA Link
02/2022 - 01/2003
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 08/2010
5Cytotoxins (Cytolysins)IBA
04/2019 - 07/2004
5AnthracyclinesIBA
08/2018 - 01/2005
5TamoxifenFDA LinkGeneric
01/2017 - 11/2003
5Methotrexate (Mexate)FDA LinkGeneric
04/2016 - 11/2002
4BilirubinIBA
10/2023 - 06/2009
4AlbuminsIBA
10/2023 - 09/2005
4ParaffinIBA
10/2021 - 09/2004
4Phenobarbital (Luminal)FDA Link
07/2021 - 06/2009
4Monoclonal AntibodiesIBA
01/2021 - 09/2014
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2020 - 06/2009
4Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
04/2019 - 04/2004
4GlucocorticoidsIBA
08/2018 - 10/2005
4Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2018 - 01/2011
4Interleukin-6 (Interleukin 6)IBA
01/2018 - 07/2004
47-hydroxy-6-methoxyphthalide (MA-1)IBA
02/2017 - 11/2011
4TOR Serine-Threonine KinasesIBA
02/2016 - 12/2010
4tigatuzumabIBA
10/2015 - 05/2011

Therapy/Procedure

115Therapeutics
12/2023 - 11/2003
83Drug Therapy (Chemotherapy)
09/2023 - 01/2002
31Radiotherapy
12/2023 - 02/2007
8Immunotherapy
12/2023 - 08/2016
8Chemoradiotherapy
01/2023 - 03/2004
7Salvage Therapy
01/2020 - 07/2009
6Combination Drug Therapy (Combination Chemotherapy)
01/2020 - 11/2002
5Surgical Instruments (Clip)
07/2016 - 06/2009
4Hepatectomy
01/2022 - 07/2012
4Aftercare (After-Treatment)
01/2018 - 10/2011
4Molecular Targeted Therapy
04/2016 - 08/2010